CD36 in Atherosclerosis: Multifaceted Regulatory Roles and the Power of Targeted Antibody Research Tools

Literature Information

This article dissects the multifaceted and critical regulatory roles of the class B scavenger receptor CD36 in the initiation and progression of atherosclerosis, unraveling its molecular characteristics and functional mechanisms across diverse vascular cell types including endothelial cells, vascular smooth muscle cells, macrophages and platelets. It also elucidates the indispensable application value of specific CD36 detection tools in atherosclerosis research and translational medicine. The Rabbit Anti-Human CD36 Antibody (Cat. No.: S0B5233)—independently developed and produced by ANT BIO PTE. LTD.—serves as a core high-specificity research tool throughout this study, enabling precise detection and functional analysis of CD36 in all key experimental and research scenarios. This research deepens the understanding of CD36 as a central regulatory node in atherosclerotic pathogenesis and lays a solid foundation for developing CD36-targeted therapeutic strategies for cardiovascular diseases, with ANT BIO’s high-performance antibody empowering every step of mechanistic exploration and translational research.

Research Background

Atherosclerosis is a chronic, progressive vascular inflammatory disease and the primary pathological basis of major cardiovascular and cerebrovascular disorders such as coronary heart disease, myocardial infarction and stroke, posing a severe global threat to human health. Its pathogenesis is highly complex, involving the dysfunction of multiple vascular cell types, abnormal lipid metabolism, persistent inflammatory responses, and thrombotic events. As an 88 kDa transmembrane glycoprotein belonging to the class B scavenger receptor family, CD36 is widely expressed on the surface of various vascular and immune cells, and has emerged as a key molecular mediator in atherosclerotic development due to its diverse ligand-binding capabilities and complex signal transduction functions.

CD36 mediates the uptake of modified lipids such as oxidized low-density lipoprotein (ox-LDL), regulates fatty acid metabolism, and participates in cell activation, inflammatory response and immune regulation—all core processes in atherosclerosis. Despite extensive research on CD36, its precise molecular mechanisms in regulating different cell type functions and driving atherosclerotic lesion formation remain to be fully elucidated. The development of high-specificity, high-affinity CD36 detection and functional research tools is therefore critical for in-depth exploration of its biological roles and the development of targeted therapeutic interventions. ANT BIO PTE. LTD.’s Rabbit Anti-Human CD36 Antibody is engineered to meet this research need, providing a reliable and versatile tool for CD36-related atherosclerosis research.

Research Rationale

Deciphering CD36’s Molecular Characteristics and Post-Translational Modification Network

The research first set out to systematically characterize CD36’s molecular structure, gene localization and post-translational modification patterns, hypothesizing that its complex modification network (ubiquitination, palmitoylation, phosphorylation, glycosylation) is the molecular basis for its diverse functional regulation in atherosclerosis. The research team aimed to map the key modification sites and their regulatory enzymes, clarifying how these modifications modulate CD36’s membrane localization, stability and signal transduction capacity.

Elucidating CD36’s Functional Roles in Key Vascular Cell Type Dysfunction

A core research objective was to dissect CD36’s cell-type-specific functions in the major vascular cell types involved in atherosclerosis—endothelial cells, vascular smooth muscle cells (VSMCs) and macrophages. The research designed a series of in vitro and in vivo experiments (including cell-specific knockout models) to investigate how CD36 mediates endothelial lipid accumulation, VSMC migration and proliferation, and macrophage foam cell formation and inflammatory activation, establishing the causal link between CD36 dysfunction and atherosclerotic lesion initiation and progression.

Investigating CD36’s Role in Atherosclerotic Thrombotic Complications

The research also aimed to explore CD36’s function in platelet activation and thrombus formation, a critical pathological event following atherosclerotic plaque rupture. It sought to clarify the molecular mechanisms by which platelet CD36 promotes platelet activation and thrombus formation, and its clinical relevance in coronary artery disease and thrombotic complications.

Validating the Application Value of CD36-Specific Antibodies in Atherosclerosis Research

Finally, the research set out to define the multifaceted application value of rabbit anti-human CD36 antibodies in basic and translational atherosclerosis research, including their use in CD36 detection, localization, interaction analysis and functional blockade. It aimed to establish the antibody as an indispensable tool for mechanistic exploration, drug development and biomarker discovery in CD36-related cardiovascular researResearch Outcomes

This research systematically unravels the multifaceted regulatory roles of CD36 in atherosclerosis and its underlying molecular mechanisms, yielding a series of key findings that advance the understanding of atherosclerotic pathogenesis and validate the critical application value of CD36-specific antibodies:

1. CD36 possesses a unique molecular structure and a complex post-translational modification network: CD36 is encoded by a gene on chromosome 7q11.2, consisting of 472 amino acids with two transmembrane domains, short cytoplasmic tails and a large glycosylated extracellular domain. Its function is tightly regulated by four major post-translational modifications: ubiquitination (Lys469/472, mediated by Parkin/USP14) modulates protein stability; palmitoylation (Cys3/7/464/466, by DHHC4/5) regulates membrane localization; phosphorylation (Thr93/Ser237, by PKC/PKA/IAP) modulates signal transduction; and 10 extracellular glycosylation sites affect ligand binding. This complex modification network collectively fine-tunes CD36’s biological activity, forming the molecular basis for its diverse roles in atherosclerosis.
2. CD36 is an initiator of endothelial cell dysfunction in early atherosclerosis: CD36 is highly expressed on aortic endothelial cells and upregulated under ox-LDL stimulation or high-fat diet conditions. It mediates the endocytic uptake of ox-LDL and modified lipids, promoting subendothelial lipid accumulation and initiating early atherosclerotic lesions. CD36 also forms a positive feedback loop between fatty acid binding and ox-LDL uptake by enhancing intracellular lipid esterification. Endothelial cell-specific CD36 knockout mice exhibit reduced long-chain fatty acid transport, improved glucose tolerance and decreased cardiac lipid deposition, confirming CD36 as a key regulator of endothelial lipid metabolism and a potential therapeutic target for early atherosclerosis.
3. CD36 drives vascular smooth muscle cell dysfunction and vascular remodeling: CD36 expression is upregulated in VSMCs during atherosclerosis, mediating lipid metabolism disorders and immune response dysregulation. Ox-LDL induces the expression of G-CSF and GM-CSF in VSMCs via CD36 signaling, enhancing VSMC migration from the media to the intima and promoting neointima formation and vascular wall thickening. CD36-deficient VSMCs show reduced proliferation due to suppressed cyclin A expression, and CD36 also modulates arterial wall inflammatory responses as a pattern recognition receptor, highlighting its role in vascular remodeling and atherosclerotic progression.
4. CD36 is a central regulator of macrophage foam cell formation and inflammatory activation: Macrophage transformation into foam cells via ox-LDL uptake is a key step in atherosclerotic plaque formation, and CD36 is the core scavenger receptor mediating this process. Ox-LDL upregulates CD36 expression through PPARγ activation, forming a positive feedback loop that accelerates lipid accumulation. CD36 also regulates macrophage function via multiple mechanisms: activating NADPH oxidase to generate ROS; modulating mitochondrial metabolic reprogramming (shifting toward glycolysis); regulating macrophage migration and retention in plaques; and promoting pro-inflammatory cytokine (TNF-α, IL-6) secretion. CD36-deficient macrophages exhibit enhanced oxidative phosphorylation and M1 polarization under ox-LDL stimulation, confirming CD36’s critical role in macrophage inflammatory metabolic reprogramming.
5. CD36 promotes atherosclerotic thrombotic complications via platelet activation: As an important platelet surface receptor, CD36 binds multiple endogenous and exogenous ligands, activating platelet signaling pathways (Src family kinases, Vav, NADPH oxidase) and promoting platelet hyperactivation. Advanced glycation end products accelerate thrombus formation through platelet CD36, and CD36-deficient mice show delayed occlusive thrombus formation in thrombosis models. Clinical studies confirm elevated platelet CD36 expression in coronary artery disease patients, and these platelets promote monocyte polarization and foam cell formation in a CD36-dependent manner, establishing CD36’s role in atherosclerotic thrombotic events.
6. CD36-specific antibodies are indispensable tools for atherosclerosis research and translation: Rabbit anti-human CD36 antibodies enable precise detection and functional analysis of CD36 across multiple research platforms: immunohistochemistry for CD36 expression distribution in vascular tissues; flow cytometry for quantitative analysis in different cell populations; co-immunoprecipitation for studying CD36-protein interactions; and functional blockade models for assessing CD36’s causal role in atherosclerosis. In translational research, the antibody supports the development of CD36-targeted therapies, serves as a tool for detecting soluble CD36 as a potential atherosclerosis biomarker, and assists in studying CD36 gene polymorphism and disease susceptibility associations.

Product Empowerment: The Pivotal Role of ANT BIO’s Rabbit Anti-Human CD36 Antibody in Atherosclerosis Research

The Rabbit Anti-Human CD36 Antibody (Cat. No.: S0B5233) independently developed and produced by ANT BIO PTE. LTD. is an indispensable core research tool that underpins all aspects of CD36-related atherosclerosis research, with its exceptional performance and versatility empowering mechanistic exploration, translational research and drug development:

1. High specificity and multifunctional detection enable precise CD36 analysis: The antibody accurately recognizes the human CD36 antigen with high specificity for CD36-expressing cell types including macrophages, platelets, microvascular endothelial cells and adipocytes. It supports diverse detection scenarios including cell surface staining, intracellular protein analysis and tissue localization, enabling precise mapping of CD36 expression and distribution in all key vascular cell types and atherosclerotic lesions— a foundational requirement for dissecting its cell-type-specific functions.
2. Superior affinity and sensitivity for endogenous CD36 detection: The antibody exhibits high binding affinity for CD36, enabling the sensitive detection of endogenous CD36 protein levels in primary cells, cell lines and tissue samples without overexpression. This allows for the accurate quantification of CD36 expression changes under physiological and pathological conditions (e.g., ox-LDL stimulation, high-fat diet), providing critical data for studying CD36’s regulatory mechanisms in atherosclerosis.
3. Validated performance across multiple key experimental platforms: Rigorously validated for use in flow cytometry, Western Blot and immunohistochemistry—three core techniques in atherosclerosis research—the antibody delivers consistent, reliable results across different experimental approaches. This cross-platform compatibility allows researchers to integrate CD36 detection data from multiple techniques, providing a comprehensive understanding of CD36’s expression, localization and functional changes in atherosclerotic pathogenesis.
4. Excellent batch consistency supports long-term and collaborative research: Manufactured under strict quality control standards with standardized immune serum management and purification processes, the antibody exhibits minimal inter-batch variation. This ensures the reproducibility of experimental results across different research batches, laboratories and multi-center collaborative studies—critical for longitudinal research on atherosclerotic progression and preclinical drug development.
5. Broad application value across interdisciplinary research areas: Beyond atherosclerosis research, the antibody is a powerful tool for CD36-related research in lipid metabolism, platelet function, angiogenesis, tumor immunology and metabolic diseases. Its ability to detect CD36 in diverse cell types and tissues makes it a versatile asset for cross-disciplinary studies, facilitating the exploration of CD36’s conserved and tissue-specific functions across different pathological processes.
6. Comprehensive technical support optimizes experimental success: ANT BIO PTE. LTD. provides full technical documentation for the antibody, including specificity validation data, optimized experimental protocols for all supported platforms, and professional technical consultation. This comprehensive support lowers the technical barrier to using the antibody, ensuring researchers can obtain accurate and reliable results even for complex primary cell and tissue samples commonly used in atherosclerosis research.

ANT BIO PTE. LTD.’s Rabbit Anti-Human CD36 Antibody is a high-performance research tool engineered for the rigorous demands of cardiovascular and metabolic disease research. Its exceptional specificity, affinity, cross-platform performance and batch consistency make it the gold-standard detection tool for CD36, empowering groundbreaking research into the molecular mechanisms of atherosclerosis and the development of novel CD36-targeted therapeutic strategies for cardiovascular diseases.

Related Product List

All products are independently developed and produced by ANT BIO PTE. LTD., providing high-performance research tools for CD36-related research in atherosclerosis, lipid metabolism, platelet function and cardiovascular disease drug development:

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.